Latest News

The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection, when given in a 3-drug anti-HIV combination. These results come from the ODYSSEY trial which was presented yesterday at the Conference on Retroviruses and Opportunistic Infections. Dolutegravir has a number of potential advantages, including: Few drug-to-drug interactions, making it easier to ...

Men who have had surgery for early stage testicular cancer can avoid potentially harmful scans.
Tribute to Professor James Hakim